Eribulin mesylate + Capecitabine
Phase 1/2Completed 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer
Trial Timeline
Jan 26, 2010 → Oct 13, 2015
NCT ID
NCT01323530About Eribulin mesylate + Capecitabine
Eribulin mesylate + Capecitabine is a phase 1/2 stage product being developed by Eisai for Metastatic Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01323530. Target conditions include Metastatic Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Breast Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01439282 | Phase 2 | Completed |
| NCT01323530 | Phase 1/2 | Completed |
| NCT00337103 | Phase 3 | Completed |
Competing Products
20 competing products in Metastatic Breast Cancer